Top

Cancer Chemotherapy and Pharmacology

Published in:

01-03-2014 | Review Article

Autophagy, a novel target for chemotherapeutic intervention of thyroid cancer

Authors: Le-chen Li, Guo-dong Liu, Xin-jie Zhang, Yan-bo Li

Published in: Cancer Chemotherapy and Pharmacology | Issue 3/2014

Abstract

Purpose

Thyroid cancers with unsatisfactory curative effect nowadays are the most common malignant tumors of the endocrine system. Apoptosis evasion, a hallmark of cancer, has driven the search of stimulating novel cell death way in cancer therapy. This review aims to explore the relationship between autophagy and thyroid cancer, especially the chemotherapy agents which are based on autophagy in treating thyroid cancers.

Methods

A computerized literature search of MEDLINE was performed using the following search terms: autophagy and thyroid cancer.

Results

Recent studies have found that several chemotherapeutic agents and knockdown of specific microRNA may contribute to autophagic tumor cell death in most thyroid cancer types.

Conclusions

Stimulating autophagy may be an effective alternative treatment to most types of thyroid cancer.

Miniño AM, Murphy SL, Xu J, Kochanek KD (2011) Deaths: final data for 2008. Natl Vital Stat Rep 59:1–126PubMed

Sipos JA, Mazzaferri EL (2010) Thyroid cancer epidemiology and prognostic variables. Clin Oncol (R Coll Radiol) 22:395–404. doi:10.1016/j.clon.2010.05.004 CrossRef

Kilfoy BA, Zheng T, Holford TR, Han X (2009) International patterns and trends in thyroid cancer incidence, 1973–2002. Cancer Causes Control 20:525–531. doi:10.1007/s10552-008-9260-4 PubMedCentralPubMedCrossRef

Mizushima N (2007) Autophagy: process and function. Genes Dev 21:2861–2873PubMedCrossRef

Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674. doi:10.1016/j PubMedCrossRef

Hundahl SA, Fleming ID, Fremgen AM, Menck HR (1998) A national cancer data base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985–1995. Cancer 83:2638–2648PubMedCrossRef

Matuszczyk A, Petersen S, Bockisch A, Gorges R, Sheu SY, Veit P, Mann K (2008) Chemotherapy with doxorubicin in progressive medullary and thyroid carcinoma of the follicular epithelium. Horm Metab Res 40:210–213. doi:10.1055/s-2008-1046781 PubMedCrossRef

Lin CI, Whang EE, Abramson MA, Jiang X, Price BD, Donner DB, Moore FD Jr, Ruan DT (2009) Autophagy: a new target for advanced papillary thyroid cancer therapy. Surgery 146:1208–1214. doi:10.1016/j.surg.2009.09.019 PubMedCrossRef

Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W (2006) European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 154:787–803PubMedCrossRef

10.

Gilliland FD, Hunt WC, Morris DM, Key CR (1997) Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the surveillance, epidemiology and end results (SEER) program 1973–1991. Cancer 79:564–573PubMedCrossRef

11.

Leboulleux S, Baudin E, Travagli JP, Schlumberger M (2004) Medullary thyroid carcinoma. Clin Endocrinol 61:299–310CrossRef

12.

Buytaert E, Callewaert G, Vandenheede JR, Agostinis P (2006) Deficiency in apoptotic effectors Bax and Bak reveals an autophagic cell death pathway initiated by photodamage to the endoplasmic reticulum. Autophagy 2:238–240PubMed

13.

Yeung S-CJ, She M, Yang H, Pan J, Sun L, Chaplin D (2007) Combination chemotherapy including combretastatin A4 phosphate and paclitaxel is effective against anaplastic thyroid cancer in a nude mouse xenograft model. J Clin Endocrinol Metab 92:2902–2909PubMedCrossRef

14.

Codogno P, Meijer AJ (2005) Autophagy and signaling: their role in cell survival and cell death. Cell Death Differ 12(Suppl 2):1509–1518PubMedCrossRef

15.

Agarwala SS, Case S (2010) Everolimus (RAD001) in the treatment of advanced renal cell carcinoma: a review. Oncologist 15:236–245. doi:10.1634/theoncologist.2009-0141 PubMedCrossRef

16.

Jeffers M, Schmidt L, Nakaigawa N, Webb CP, Weirich G, Kishida T, Zbar B, Vande Woude GF (1997) Activating mutations for the met tyrosine kinase receptor in human cancer. Proc Natl Acad Sci USA 94:11445–11450PubMedCentralPubMedCrossRef

17.

Abraham D, Jackson N, Gundara JS, Zhao J, Gill AJ, Delbridge L, Robinson BG, Sidhu SB (2011) MicroRNA profiling of sporadic and hereditary medullary thyroid cancer identifies predictors of nodal metastasis, prognosis, and potential therapeutic targets. Clin Cancer Res 17:4772–4781. doi:10.1158/1078-0432.CCR-11-0242 PubMedCrossRef

18.

Li J, Fu H, Xu C, Tie Y, Xing R, Zhu J, Qin Y, Sun Z, Zheng X (2010) miR-183 inhibits TGF-beta1-induced apoptosis by downregulation of PDCD4 expression in human hepatocellular carcinoma cells. BMC Cancer 10:354. doi:10.1186/1471-2407-10-354 PubMedCentralPubMedCrossRef

19.

Wang G, Mao W, Zheng S (2008) MicroRNA-183 regulates Ezrin expression in lung cancer cells. FEBS Lett 582:3663–3668. doi:10.1016/j.febslet.2008.09.051 PubMedCrossRef

20.

Anastasia L, Pelissero G, Venerando B, Tettamanti G (2010) Cell reprogramming: expectations and challenges for chemistry in stem cell biology and regenerative medicine. Cell Death Differ 17:1230–1237. doi:10.1038/cdd.2010.14 PubMedCrossRef

21.

Jemaà M, Galluzzi L, Kepp O, Boilève A, Lissa D, Senovilla L, Harper F, Pierron G, Berardinelli F, Antoccia A, Castedo M, Vitale I, Kroemer G (2012) Preferential killing of p53-deficient cancer cells by reversine. Cell Cycle 11:2149–2158. doi:10.4161/cc.20621 PubMedCrossRef

22.

Nikiforov YE (2004) Genetic alterations involved in the transition from well-differentiated to poorly differentiated and anaplastic thyroid carcinomas. Endocr Pathol 15:319–327PubMedCrossRef

23.

Lee YR, Wu WC, Ji WT, Chen JY, Cheng YP, Chiang MK, Chen HR (2012) Reversine suppresses oral squamous cell carcinoma via cell cycle arrest and concomitantly apoptosis and autophagy. J Biomed Sci 19:9. doi:10.1186/1423-0127-19-9 PubMedCrossRef

24.

Hua SC, Chang TC, Chen HR, Lu CH, Liu YW, Chen SH, Yu HI, Chang YP, Lee YR (2012) Reversine, a 2,6-disubstituted purine, as an anti-cancer agent in differentiated and undifferentiated thyroid cancer cells. Pharm Res 29:1990–2005. doi:10.1007/s11095-012-0727-3 PubMedCrossRef

25.

D’Alise AM, Amabile G, Iovino M, Di Giorgio FP, Bartiromo M, Sessa F, Villa F, Musacchio A, Cortese R (2008) Reversine, a novel Aurora kinases inhibitor, inhibits colony formation of human acute myeloid leukemia cells. Mol Cancer Ther 7:1140–1149. doi:10.1158/1535-7163.MCT-07-2051 PubMedCrossRef

26.

McMillin DW, Delmore J, Weisberg E, Negri JM, Geer DC, Klippel S, Mitsiades N, Schlossman RL, Munshi NC, Kung AL, Griffin JD, Richardson PG, Anderson KC, Mitsiades CS (2010) Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. Nat Med 16:483–489. doi:10.1038/nm.2112 PubMedCentralPubMedCrossRef

27.

Lu C-H, Liu Y-W, Hua S-C, Yu H-I, Chang Y-P, Lee Y-R (2012) Autophagy induction of reversine on human follicular thyroid cancer cells. Biomed Pharmacother 66:642–647. doi:10.1016/j.biopha.2012.08.001 PubMedCrossRef

28.

Lin C-I, Whang EE, Lorch JH, Ruan DT (2012) Autophagic activation potentiates the antiproliferative effects of tyrosine kinase inhibitors in medullary thyroid cancer. Surgery 152:1142–1149. doi:10.1016/j.surg.2012.08.016 PubMedCrossRef

29.

Elisei R, Cosci B, Romei C, Bottici V, Renzini G, Molinaro E, Agate L, Vivaldi A, Faviana P, Basolo F, Miccoli P, Berti P, Pacini F, Pinchera A (2008) Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J Clin Endocrinol Metab 93:682–687PubMedCrossRef

30.

Komatsu M, Waguri S, Ueno T, Iwata J, Murata S, Tanida I, Ezaki J, Mizushima N, Ohsumi Y, Uchiyama Y, Kominami E, Tanaka K, Chiba T (2005) Impairment of starvation-induced and constitutive autophagy in Atg7-deficient mice. J Cell Biol 169:425–434PubMedCrossRef

31.

Hailey DW, Rambold AS, Satpute-Krishnan P, Mitra K, Sougrat R, Kim PK, Lippincott-Schwartz J (2010) Mitochondria supply membranes for autophagosome biogenesis during starvation. Cell 141:656–667. doi:10.1016/j.cell.2010.04.009 PubMedCentralPubMedCrossRef

32.

Mizushima N, Levine B (2010) Autophagy in mammalian development and differentiation. Nat Cell Biol 12(9):823–830. doi:10.1038/ncb0910-823 PubMedCentralPubMedCrossRef

33.

White E, Karp C, Strohecker AM, Guo Y, Mathew R (2010) Role of autophagy in suppression of inflammation and cancer. Curr Opin Cell Biol 22:212–217. doi:10.1016/j.ceb.2009.12.008 PubMedCentralPubMedCrossRef

34.

He C, Klionsky DJ (2009) Regulation mechanisms and signaling pathways of autophagy. Annu Rev Genet 43:67–93. doi:10.1146/annurev-genet-102808-114910 PubMedCentralPubMedCrossRef

35.

Barth S, Glick D, Macleod KF (2010) Autophagy: assays and artifacts. J Pathol 221:117–124. doi:10.1002/path.2694 PubMedCentralPubMedCrossRef

36.

Lum JJ, DeBerardinis RJ, Thompson CB (2005) Autophagy in metazoans: cell survival in the land of plenty. Nat Rev Mol Cell Biol 6:439–448PubMedCrossRef

37.

Ravikumar B, Vacher C, Berger Z, Davies JE, Luo S, Oroz LG, Scaravilli F, Easton DF, Duden R, O’Kane CJ, Rubinsztein DC (2004) Inhibition of mTOR induces autophagy and reduces toxicity of poly glutamine expansions in fly and mouse models of Huntington disease. Nat Genet 36:585–595PubMedCrossRef

38.

Kanazawa T, Taneike I, Akaishi R, Yoshizawa F, Furuya N, Fujimura S, Kadowaki M (2004) Amino acids and insulin control autophagic proteolysis through different signaling pathways in relation to mTOR in isolated rat hepatocytes. J Biol Chem 279:8452–8459PubMedCrossRef

39.

Suzuki K, Ohsumi Y (2007) Molecular machinery of autophagosome formation in yeast, Saccharomyces cerevisiae. FEBS Lett 581:2156–2161PubMedCrossRef

40.

Das G, Shravage BV, Baehrecke EH (2012) Regulation and function of autophagy during cell survival and cell death. Cold Spring Harb Perspect Biol 4(6). doi:10.1101/cshperspect.a008813

41.

Rubinsztein DC, Codogno P, Levine B (2012) Autophagy modulation as a potential therapeutic target for diverse diseases. Nat Rev Drug Discov 11:709–730. doi:10.1038/nrd3802 PubMedCentralPubMedCrossRef

42.

Rouschop KM, Wouters BG (2009) Regulation of autophagy through multiple independent hypoxic signaling pathways. Curr Mol Med 9:417–424PubMedCrossRef

43.

Amaravadi RK, Lippincott-Schwartz J, Yin XM, Weiss WA, Takebe N, Timmer W, DiPaola RS, Lotze MT, White E (2011) Principles and current strategies for targeting autophagy for cancer treatment. Clin Cancer Res 17:654–666. doi:10.1158/1078-0432.CCR-10-2634 PubMedCentralPubMedCrossRef

44.

White E, DiPaola RS (2009) The double-edged sword of autophagy modulation in cancer. Clin Cancer Res 15:5308–5316. doi:10.1158/1078-0432.CCR-07-5023 PubMedCentralPubMedCrossRef

45.

Chen N, Karantza-Wadsworth V (2009) Role and regulation of autophagy in cancer. Biochim Biophys Acta 1793:1516–1523. doi:10.1016/j.bbamcr.2008.12.013 PubMedCentralPubMedCrossRef

46.

Chen S, Rehman SK, Zhang W, Wen A, Yao L, Zhang J (2010) Autophagy is a therapeutic target in anticancer drug resistance. Biochim Biophys Acta 1806:220–229. doi:10.1016/j.bbcan.2010.07.003 PubMed

47.

Gozuacik D, Kimchi A (2007) Autophagy and cell death. Curr Top Dev Biol 78:217–245PubMedCrossRef

48.

Crighton D, Wilkinson S, O’Prey J, Syed N, Smith P, Harrison PR, Gasco M, Garrone O, Crook T, Ryan KM (2006) DRAM, a p53-induced modulator of autophagy, is critical for apoptosis. Cell 126:121–134PubMedCrossRef

49.

Pattingre S, Tassa A, Qu X, Garuti R, Liang XH, Mizushima N, Packer M, Schneider MD, Levine B (2005) Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. Cell 122:927–939PubMedCrossRef

50.

Feng W, Huang S, Wu H, Zhang M (2007) Molecular basis of Bcl-xL’s target recognition versatility revealed by the structure of Bcl-xL in complex with the BH3 domain of Beclin 1. J Mol Biol 372:223–235PubMedCrossRef

51.

Lambert LA, Qiao N, Hunt KK, Lambert DH, Mills GB, Meijer L, Keyomarsi K (2008) Autophagy: a novel mechanism of synergistic cytotoxicity between doxorubicin and roscovitine in a sarcoma model. Cancer Res 68:7966–7974. doi:10.1158/0008-5472.CAN-08-1333 PubMedCentralPubMedCrossRef

52.

Muñoz-Gámez JA, Rodríguez-Vargas JM, Quiles-Pérez R, Aguilar-Quesada R, Martín-Oliva D, de Murcia G, Menissier de Murcia J, Almendros A, Ruiz de Almodóvar M, Oliver FJ (2009) PARP-1 is involved in autophagy induced by DNA damage. Autophagy 5:61–74PubMedCrossRef

53.

Easton JB, Houghton PJ (2006) mTOR and cancer therapy. Oncogene 25:6436–6446PubMedCrossRef

54.

Johnson BE, Jackman D, Janne PA (2007) Rationale for a phase I trial of erlotinib and the mammalian target of rapamycin inhibitor everolimus (RAD001) for patients with relapsed non small cell lung cancer. Clin Cancer Res 13:s4628–s4631PubMedCrossRef

55.

Motoyama K, Inoue H, Takatsuno Y, Tanaka F, Mimori K, Uetake H, Sugihara K, Mori M (2009) Over- and under-expressed microRNAs in human colorectal cancer. Int J Oncol 34:1069–1075PubMed

56.

Lin WM, Baker AC, Beroukhim R, Winckler W, Feng W, Marmion JM, Laine E, Greulich H, Tseng H, Gates C, Hodi FS, Dranoff G, Sellers WR, Thomas RK, Meyerson M, Golub TR, Dummer R, Herlyn M, Getz G, Garraway LA (2008) Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res 68:664–673. doi:10.1158/0008-5472.CAN-07-2615 PubMedCrossRef

57.

Wang G, Mao W, Zheng S (2008) MicroRNA-183 regulates Ezrin expression in lung cancer cells. FEBS Lett 582:3663–3668. doi:10.1016/j.febslet.2008.09.051 PubMedCrossRef

58.

Nakahara S, Oka N, Raz A (2005) On the role of galectin-3 in cancer apoptosis. Apoptosis 10:267–275PubMedCrossRef

59.

Idikio HA (2011) Galectin-3 and beclin1/Atg6 genes in human cancers: using cDNA tissue panel, qRT-PCR, and logistic regression model to identify cancer cell biomarkers. PLoS ONE 6:e26150. doi:10.1371/journal.pone.0026150 PubMedCentralPubMedCrossRef

60.

Mizushima N (2005) The pleiotropic role of autophagy: from protein metabolism to bactericide. Cell Death Differ 12(Suppl 2):1535–1541CrossRef

61.

Lin YC, Lin JH, Chou CW, Chang YF, Yeh SH, Chen CC (2008) Statins increase p21 through inhibition of histone deacetylase activity and release of promoter-associated HDAC1/2. Cancer Res 68:2375–2383. doi:10.1158/0008-5472.CAN-07-5807 PubMedCrossRef

62.

Sassano A, Platanias LC (2008) Statins in tumor suppression. Cancer Lett 260:11–19. doi:10.1016/j.canlet.2007.11.036 PubMedCrossRef

63.

Zeybek ND, Gulcelik NE, Kaymaz FF, Sarisozen C, Vural I, Bodur E, Canpinar H, Usman A, Asan E (2011) Rosuvastatin induces apoptosis in cultured human papillary thyroid cancer cells. J Endocrinol 210:105–115. doi:10.1530/JOE-10-0411 PubMedCrossRef

64.

Scott RC, Juhász G, Neufeld TP (2007) Direct induction of autophagy by Atg1 inhibits cell growth and induces apoptotic cell death. Curr Biol 17:1–11PubMedCentralPubMedCrossRef

65.

Tsujimoto Y, Shimizu S (2005) Another way to die: autophagic programmed cell death. Cell Death Differ 12(Suppl 2):1528–1534CrossRef

66.

Thorburn A (2008) Apoptosis and autophagy: regulatory connections between two supposedly different processes. Apoptosis 13:1–9PubMedCentralPubMedCrossRef

67.

Shi M, Zhang T, Sun L, Luo Y, Liu DH, Xie ST, Song XY, Wang GF, Chen XL, Zhou BC, Zhang YZ (2013) Calpain, Atg5 and Bak play important roles in the crosstalk between apoptosis and autophagy induced by influx of extracellular calcium. Apoptosis 18:435–451. doi:10.1007/s10495-012-0786-2 PubMedCrossRef

68.

Sarbassov DD, Ali SM, Sabatini DM (2005) Growing roles for the mTOR pathway. Curr Opin Cell Biol 17:596–603PubMedCrossRef

69.

Corcelle EA, Puustinen P, Jaattela M (2009) Apoptosis and autophagy: targeting autophagy signalling in cancer cells—‘trick or treats’? FEBS J 276:6084–6096. doi:10.1111/j.1742-4658.2009.07332.x PubMedCrossRef

70.

Chan EY, Kir S, Tooze SA (2007) siRNA screening of the kinome identifies ULK1 as a multidomain modulator of autophagy. J Biol Chem 282:25464–25474PubMedCrossRef

71.

He C, Klionsky DJ (2009) Regulation mechanisms and signaling pathways of autophagy. Annu Rev Genet 43:67–93PubMedCentralPubMedCrossRef

72.

Zou CF, Jia L, Jin H, Yao M, Zhao N, Huan J, Lu Z, Bast RC Jr, Feng Y, Yu Y (2011) Re-expression of ARHI (DIRAS3) induces autophagy in breast cancer cells and enhances the inhibitory effect of paclitaxel. BMC Cancer 11:22. doi:10.1186/1471-2407-11-22 PubMedCentralPubMedCrossRef

73.

Eum KH, Lee M (2011) Crosstalk between autophagy and apoptosis in the regulation of paclitaxel-induced cell death in v-Ha-ras-transformed fibroblasts. Mol Cell Biochem 348:61–68. doi:10.1007/s11010-010-0638-8 PubMedCrossRef

74.

Yang PM, Chen CC (2011) Life or death? Autophagy in anticancer therapies with statins and histone deacetylase inhibitors. Autophagy 7:107–108PubMedCrossRef

75.

Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674. doi:10.1016/j.cell.2011.02.013 PubMedCrossRef

76.

Maiuri MC, Zalckvar E, Kimchi A, Kroemer G (2007) Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nat Rev Mol Cell Biol 8:741–752PubMedCrossRef

77.

Platini F, Perez-Tomas R, Ambrosio S, Tessitore L (2010) Understanding autophagy in cell death control. Curr Pharm Des 16:101–113PubMedCrossRef

78.

Yue Z, Jin S, Yang C, Levine AJ, Heintz N (2003) Beclin 1, an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor. Proc Natl Acad Sci USA 100:15077–15082PubMedCrossRef

79.

Takamura A, Komatsu M, Hara T, Sakamoto A, Kishi C, Waguri S, Eishi Y, Hino O, Tanaka K, Mizushima N (2011) Autophagy-deficient mice develop multiple liver tumors. Genes Dev 25:795–800. doi:10.1101/gad.2016211 PubMedCrossRef

80.

Miracco C, Cevenini G, Franchi A, Luzi P, Cosci E, Mourmouras V, Monciatti I, Mannucci S, Biagioli M, Toscano M, Moretti D, Lio R, Massi D (2010) Beclin 1 and LC3 autophagic gene expression in cutaneous melanocytic lesions. Hum Pathol 41:503–512. doi:10.1016/j.humpath.2009.09.004 PubMedCrossRef

81.

82.

Wang RC, Wei Y, An Z, Zou Z, Xiao G, Bhagat G, White M, Reichelt J, Levine B (2012) Akt-mediated regulation of autophagy and tumorigenesis through Beclin 1 phosphorylation. Science 338:956–959. doi:10.1126/science.122596 PubMedCentralPubMedCrossRef

83.

Mathew R, Kongara S, Beaudoin B, Karp CM, Bray K, Degenhardt K, Chen G, Jin S, White E (2007) Autophagy suppresses tumor progression by limiting chromosomal instability. Genes Dev 21:1367–1381PubMedCrossRef

84.

Mathew R, Karp CM, Beaudoin B, Vuong N, Chen G, Chen HY, Bray K, Reddy A, Bhanot G, Gelinas C, Dipaola RS, Karantza-Wadsworth V, White E (2009) Autophagy suppresses tumorigenesis through elimination of p62. Cell 137:1062–1075. doi:10.1016/j.cell.2009.03.048 PubMedCentralPubMedCrossRef

85.

Degenhardt K, Mathew R, Beaudoin B, Bray K, Anderson D, Chen G, Mukherjee C, Shi Y, Gélinas C, Fan Y, Nelson DA, Jin S, White E (2006) Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. Cancer Cell 10:51–64PubMedCentralPubMedCrossRef

86.

White E (2012) Deconvoluting the context-dependent role for autophagy in cancer. Nat Rev Cancer 12:401–410. doi:10.1038/nrc3262 PubMedCentralPubMedCrossRef

87.

Kenific CM, Thorburn A, Debnath J (2010) Autophagy and metastasis: another double-edged sword. Curr Opin Cell Biol 22:241–245. doi:10.1016/j.ceb.2009.10.008 PubMedCentralPubMedCrossRef

88.

Horbinski C, Mojesky C, Kyprianou N (2010) Live free or die: tales of homeless (cells) in cancer. Am J Pathol 177:1044–1052. doi:10.2353/ajpath.2010.091270 PubMedCrossRef

89.

He C, Levine B (2010) The Beclin 1 interactome. Curr Opin Cell Biol 22:140–149. doi:10.1016/j.ceb.2010.01.001 PubMedCentralPubMedCrossRef

90.

Liu B, Cheng Y, Liu Q, Bao JK, Yang JM (2010) Autophagic pathways as new targets for cancer drug development. Acta Pharmacol Sin 31:1154–1164. doi:10.1038/aps.2010.118 PubMedCentralPubMedCrossRef

91.

Budanov AV, Karin M (2008) p53 target genes sestrin1 and sestrin2 connect genotoxic stress and mTOR signaling. Cell 134:451–460. doi:10.1016/j.cell.2008.06.028 PubMedCentralPubMedCrossRef

92.

Tasdemir E, Maiuri MC, Galluzzi L, Vitale I, Djavaheri-Mergny M, D’Amelio M, Criollo A, Morselli E, Zhu C, Harper F, Nannmark U, Samara C, Pinton P, Vicencio JM, Carnuccio R, Moll UM, Madeo F, Paterlini-Brechot P, Rizzuto R, Szabadkai G, Pierron G, Blomgren K, Tavernarakis N, Codogno P, Cecconi F, Kroemer G (2008) Regulation of autophagy by cytoplasmic p53. Nat Cell Biol 10:676–687. doi:10.1038/ncb1730 PubMedCentralPubMedCrossRef

93.

Morselli E, Galluzzi L, Kepp O, Vicencio JM, Criollo A, Maiuri MC, Kroemer G (2009) Anti- and pro-tumor functions of autophagy. Biochim Biophys Acta 1793:1524–1532. doi:10.1016/j.bbamcr.2009.01.006 PubMedCrossRef

94.

Cosse JP, Rommelaere G, Ninane N, Arnould T, Michiels C (2010) BNIP3 protects HepG2 cells against etoposide-induced cell death under hypoxia by an autophagy-independent pathway. Biochem Pharmacol 80:1160–1169. doi:10.1016/j.bcp.2010.07.009 PubMedCrossRef

95.

Lee SB, Tong SY, Kim JJ, Um SJ, Park JS (2007) Caspase-independent autophagic cytotoxicity in etoposide-treated CaSki cervical carcinoma cells DNA. Cell Biol 26:713–720

96.

Sun Y, Zhang J, Peng ZL (2009) Beclin1 induces autophagy and its potential contributions to sensitizes SiHa cells to carboplatin therapy. Int J Gynecol Cancer 19:772–776. doi:10.1111/IGC.0b013e31819d7d10 PubMedCrossRef

97.

Mukubou H, Tsujimura T, Sasaki R, Ku Y (2010) The role of autophagy in the treatment of pancreatic cancer with gemcitabine and ionizing radiation. Int J Oncol 37:821–828PubMed

98.

Shingu T, Fujiwara K, Bögler O, Akiyama Y, Moritake K, Shinojima N, Tamada Y, Yokoyama T, Kondo S (2009) Stage-specific effect of inhibition of autophagy on chemotherapy-induced cytotoxicity. Autophagy 5:537–539PubMedCrossRef

99.

Feng Z (2010) p53 regulation of the IGF-1/AKT/mTOR pathways and the endosomal compartment. Cold Spring Harb Perspect Biol 2:a001057. doi:10.1101/cshperspect.a001057 PubMedCrossRef

Title: Autophagy, a novel target for chemotherapeutic intervention of thyroid cancer
Authors: Le-chen Li
Guo-dong Liu
Xin-jie Zhang
Yan-bo Li
Publication date: 01-03-2014
Publisher: Springer Berlin Heidelberg
Published in: Cancer Chemotherapy and Pharmacology / Issue 3/2014
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-013-2363-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2014

Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers

The effect of rifampicin, a prototypical CYP3A4 inducer, on erlotinib pharmacokinetics in healthy subjects

Increased serum level of epidermal growth factor receptor (EGFR) is associated with poor progression-free survival in patients with epithelial ovarian cancer

Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors

Phase I dosage finding and pharmacokinetic study of intravenous topotecan and oral erlotinib in adults with refractory solid tumors

Intraperitoneal paclitaxel induces regression of peritoneal metastasis partly by destruction of peripheral microvessels

Keynote webinar | Spotlight on antibody–drug conjugates in cancer